{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the CI could not be estimated due to insufficient number of participants with event","groupId":"OG000","lowerLimit":"4.63","upperLimit":"NA","value":"6.1"},{"comment":"The median and upper bound of the CI could not be estimated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"5.13","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Duration of PSA response is defined as the time from the date of first documented PSA response to the earliest date of PSA progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"MEDIAN","populationDescription":"All participants in Part 1 who met criteria for a PSA response to study treatment. There were no participants in the Control Arm that were part of the PSA Response Evaluable Population. Participants in Part 2 did not have mCRPC, so were not assessed using PSA measurement.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks throughout study participation. Average duration of participation, 10 months.","title":"Part 1: Duration of PSA Response Per PCWG3 Criteria","type":"SECONDARY","unitOfMeasure":"months"}